SCHEMBL24038015

SCHEMBL24038015

CC(C)(C)Cc1ccc(OC(C)(C)C)c(N)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.46
▸ ALDH1A1 P00352 4/20 0.39
▸ MAPT P10636 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ USP2 O75604 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ CASP7 P55210 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ ESR1 P03372 1/20 0.38
▸ CYP19A1 P11511 2/20 0.35
▸ CSNK2A1 P68400 3/20 0.33
▸ SLC6A2 P23975 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ HRH1 P35367 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24037771 0.84 GAA (0.44) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL13153012 0.84 GAA (0.67) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL20718709 0.83 ESR1 (0.42) ALDH1A1KDM4EATMESR1CYP19A1
SCHEMBL24037772 0.82 GAA (0.40) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL25986451 0.80 ESR1 (0.39) MAPTKDM4EESR1THRBTHRA
SCHEMBL24038031 0.79 GAA (0.65) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL12001793 0.79 ALDH1A1 (0.48) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL26417555 0.79 ESR1 (0.38) ALDH1A1KDM4EHTTESR1KCNH2
SCHEMBL24037767 0.77 IDO1 (0.39) ESR1
SCHEMBL15156265 0.77 ESR1 (0.46) GAAALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11730817-B2 Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction INVIVOGEN (FR) 2023-08-22 — — US disclosed
US-11730817-B2 Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction INVIVOGEN (FR) 2023-08-22 — — US disclosed
US-20210353760-A1 PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION INVIVOGEN (FR) 2021-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11730817-B2 Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction STING1, CGAS, TLR9 GAA 369/4885ALDH1A1 4585/4885MAPT 4689/4885
US-20210353760-A1 PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION STING1, CGAS, TLR9 GAA 369/4885ALDH1A1 4585/4885MAPT 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback